Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes
Titel:
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes
Auteur:
Boccardo, F. Cavo, A. Zanardi, E. Fabbroni, C. Zinoli, L. Di Meglio, A. Arboscello, E. Bellodi, A. Spallarossa, P. Cattrini, C. Messina, C. Rubagotti, A.